期刊文献+

辛伐他汀缓释片在比格犬体内的药动学及生物等效性研究 被引量:1

Study on Pharmacokinetics and Bioequivalence of Simvastatin Sustained Release Tablets in Beagle Dogs
原文传递
导出
摘要 目的:研究辛伐他汀缓释片在比格犬体内的药动学和生物等效性。方法:将6只比格犬随机分成2组,分别单剂量灌服20 mg辛伐他汀缓释片(受试制剂)和市售辛伐他汀片(参比制剂),不同时间采集血样,采用液相- 质谱- 质谱联用法测定比格犬体内的血药浓度并计算药动学参数。结果:参比制剂与受试制剂的C_(max)分别为(23.461±6.043)、(13.942±3.236)ng.mL^(-1);t_(max)分别为(2.158±0.396)、(4.116±1.145 3)h;t_(1/2) 分别为(4.564±0.645)、(8.143±0.679)h;AUC_(0~24 h) 分别为(118.647±31.989)、(129.977±29.853)ng.h.mL^(-1)。结论:受试制剂与参比制剂在吸收速率方面具有显著差异,二者不具有生物等效性。 OBJECTIVE:To study pharmacokinetics and bioequivalence of Simvastatin sustained release tablets in healthy beagle dogs.METHODS:6 beagle dogs were randomized into two groups.They received oral single dose of Simvastatin sustained release tablets 20 mg(test tablet) or Simvastatin tablets for sale(reference tablet).Plasma samples were collected at different time points.Plasma concentration of simvastatin acid was determined by LC-MS/MS and pharmacokinetic parameters were calculated.RESULTS:The pharmacokinetic parameters of reference tablet vs.test tablet were as follows:Cmax:(23.461±6.043) ng·mL^-1 vs.(13.942±3.236) ng·mL^-1;tmax:(2.158±0.396) h vs.(4.116±1.145 3) h;t1/2:(4.564±0.645) h vs.(8.143±0.679) h;AUC0~24 h:(118.647±31.989) ng·h·mL^-1 vs.(129.977±29.853) ng·h·mL^-1.CONCLUSIONS:The absorption rate of test tablet is different from that of reference tablet.The two kinds of tablets are not bioequivalent.
出处 《中国药房》 CAS CSCD 北大核心 2010年第25期2347-2349,共3页 China Pharmacy
关键词 辛伐他汀缓释片 药动学 生物等效性 液相-质谱-质谱联用法 Simvastatin sustained release tablets Pharmacokinetic Bioequivalence LC-MS/MS
  • 相关文献

参考文献7

二级参考文献14

  • 1-.VIDAL 临床用药年鉴[M].北京:中信出版社,1998.517-519.
  • 2Carlucci. pharmaceutical and Biomedical[J ]. Anaglysis. 1992,10(9) :693.
  • 3李家泰,临床药理学(第2版),1998年,158页
  • 4Albe A W,Proc Natl Acad Sci USA,1980年,77卷,3957页
  • 5VIDAL临床用药年鉴,1998年,517页
  • 6Carlucci. pharmaceutical and Biomedical[J]. Anaglysis.1992,10(9):693.
  • 7Pentikainen JP, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol, 1992, 32:136
  • 8Davidson MH, Stein EA, Dujovre CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. American J of Cardiol, 1997, 79(Jan):38
  • 9Stubbs RJ, Schwartz MS, Gerson RJ, et al. Comparison of plasma profiles lovastatin (mevinolin), simvastatin (epistatin) and pravastatin (eptastatin) in the dog. Drug Invest, 1990, 2:18
  • 10Jemal M,Ouyang Z,Powell ML.Direct-injection LC-MSMS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma[J].J Pharm Biomed Anal,2000,23 (2-3):323-340.

共引文献56

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部